Retatrutide: The Complete Guide

Overview

Retatrutide represents the next frontier in incretin-based pharmacotherapy. While semaglutide (Ozempic/Wegovy) targets a single receptor (GLP-1) and tirzepatide (Mounjaro/Zepbound) targets two (GIP + GLP-1), retatrutide activates all three major metabolic hormone receptors: GIP, GLP-1, and glucagon. This triple-agonist approach addresses both sides of the energy balance equation — decreasing caloric intake through appetite suppression and increasing caloric expenditure through glucagon-driven thermogenesis.

The molecule was developed by Eli Lilly and Company and is designated by its research code LY3437943. It has no brand name yet, as it remains investigational. The Phase 2 clinical data, published in The New England Journal of Medicine and The Lancet in 2023, generated considerable excitement: participants receiving the 12 mg dose lost an average of 24.2% of body weight over 48 weeks — and the weight-loss curve had not yet plateaued, suggesting further reductions with longer treatment (Jastreboff et al., NEJM 2023).

The Phase 3 TRIUMPH program, comprising four large clinical trials, is currently underway. The first results came from TRIUMPH-4, a trial in people with obesity and knee osteoarthritis, which reported in December 2025. Participants on the 12 mg dose lost an average of 28.7% of their body weight (71.2 lbs / 32.3 kg) over 68 weeks — the largest weight reduction ever reported for a pharmaceutical agent in a controlled clinical trial (Eli Lilly press release).

Beyond weight loss, Phase 2 data showed retatrutide produced dramatic reductions in liver fat (up to 82.4% at the 12 mg dose, with 86% of participants achieving normal liver fat levels), meaningful improvements in glycemic control in type 2 diabetes (HbA1c reductions up to -2.2%), and significant blood pressure reductions — suggesting broad cardiometabolic benefits (Nature Medicine, 2024).

Retatrutide's side-effect profile is consistent with the GLP-1 drug class: gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common adverse events, particularly during dose escalation. A notable signal is an increase in heart rate of approximately 5–10 bpm, which is higher than what has been observed with semaglutide (~3–4 bpm) and warrants monitoring in larger Phase 3 trials. Discontinuation rates due to adverse events in Phase 2 ranged from 6% to 16%.

If Phase 3 results confirm the Phase 2 findings, Eli Lilly is expected to file for FDA approval (NDA) in late 2026, with potential approval in mid-2027. Retatrutide would enter a rapidly evolving market alongside tirzepatide and other next-generation agents, but its weight-loss efficacy — substantially exceeding any approved medication — positions it as a potential paradigm shift in obesity treatment.

Quick Comparison: Single vs. Dual vs. Triple Agonist

Sources: STEP 1 (NEJM), SURMOUNT-1 (NEJM), TRIUMPH-4 (Eli Lilly investor release).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Three Receptor Targets

Retatrutide's triple-agonist mechanism targets three distinct hormonal pathways, each contributing different metabolic effects:

GLP-1 (Glucagon-Like Peptide-1) Receptor

The GLP-1 pathway is the foundation of all current incretin-based obesity and diabetes drugs. GLP-1 receptor activation produces:

• Appetite suppression: GLP-1 acts on hypothalamic and brainstem appetite centers to reduce hunger and increase satiety
• Slowed gastric emptying: Food moves more slowly through the stomach, prolonging feelings of fullness
• Enhanced insulin secretion: Glucose-dependent stimulation of pancreatic beta cells to release insulin
• Glucagon suppression: Reduces post-meal glucagon release, lowering blood glucose

Retatrutide's EC50 (half-maximal effective concentration) at the GLP-1 receptor is 0.775 nM, making it a potent GLP-1 agonist comparable to semaglutide in its ability to engage this pathway.

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor

GIP is the other major incretin hormone, and its addition is what makes tirzepatide more effective than GLP-1-only drugs. GIP receptor activation contributes:

• Enhanced insulin secretion: GIP stimulates insulin release through a pathway complementary to GLP-1, producing a more robust insulin response
• Improved lipid metabolism: GIP receptors are expressed on adipocytes (fat cells), where activation improves fat handling and oxidation
• Potentiation of GLP-1 effects: Combined GIP + GLP-1 activation appears to produce greater appetite suppression and metabolic improvement than either alone
• Central appetite effects: GIP receptors in the hypothalamus contribute to energy balance regulation

Retatrutide has the highest potency at the GIP receptor, with an EC50 of 0.0643 nM — approximately 12 times more potent at GIP than at GLP-1. This strong GIP engagement is a defining feature of the molecule.

Glucagon Receptor — The Third Pathway

This is what makes retatrutide unique. The glucagon receptor is the third target, and it introduces an entirely different mechanism that no approved obesity drug exploits: increasing energy expenditure.

• Thermogenesis: Glucagon activates brown adipose tissue (BAT) and promotes the "browning" of white adipose tissue, increasing heat production and caloric expenditure
• Hepatic lipid oxidation: Glucagon stimulates the liver to burn fat for energy, reducing hepatic fat content — which likely explains the dramatic liver fat reductions seen in MASLD/NASH data
• Lipolysis: Glucagon promotes the breakdown of stored fat in adipose tissue, mobilizing fatty acids for energy
• Glycogenolysis: Glucagon triggers the breakdown of liver glycogen, which at pharmacological levels contributes to energy mobilization

Retatrutide's EC50 at the glucagon receptor is 5.79 nM — the weakest of the three pathways, but intentionally so. The lower glucagon potency is by design: enough to drive meaningful energy expenditure and lipid oxidation, but not so strong as to produce uncontrolled hyperglycemia (a known glucagon effect). The concurrent GLP-1 and GIP agonism counterbalance glucagon's glucose-raising tendency by enhancing insulin secretion.

Why Triple Is Greater Than Dual Is Greater Than Single

The evolution from single to dual to triple agonism can be understood through the energy balance equation:

Single-agonist drugs (semaglutide) work primarily by reducing caloric intake. Dual agonists (tirzepatide) enhance this effect and improve metabolic handling. Retatrutide adds the critical missing piece: increasing the caloric expenditure side of the equation. This simultaneous attack on both intake and expenditure likely explains why retatrutide's weight loss (~28.7%) substantially exceeds tirzepatide's (~22.5%) and semaglutide's (~14.9%).

Pharmacokinetics

• Half-life: Approximately 6 days, supporting once-weekly dosing
• Administration: Subcutaneous injection
• Structure: Modified peptide with a fatty acid moiety that enables albumin binding, extending circulating half-life
• Binding affinity ratio: GIP >> GLP-1 > glucagon (EC50: 0.0643 nM, 0.775 nM, 5.79 nM respectively)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Clinical Trials

Phase 2: Obesity (NCT04881760)

The pivotal Phase 2 obesity trial, published by Jastreboff et al. in the New England Journal of Medicine (2023), enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without diabetes. Participants were randomized to placebo or escalating doses of retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) for 48 weeks (NEJM; ClinicalTrials.gov).

Source: Jastreboff et al., NEJM 2023.

A critical finding: at 48 weeks, the weight-loss curves had not yet plateaued at the higher doses, suggesting that longer treatment would produce even greater reductions. This was subsequently confirmed by the TRIUMPH-4 Phase 3 results at 68 weeks.

At the 8 mg and 12 mg doses, 100% of participants achieved at least 5% weight loss — a threshold considered clinically meaningful. At 12 mg, 83% achieved ≥15% weight loss, a level associated with resolution of many obesity-related comorbidities.

Phase 2: Type 2 Diabetes (Rosenstock et al., Lancet 2023)

A parallel Phase 2 trial enrolled 281 adults with type 2 diabetes and tested retatrutide across multiple doses over 36 weeks. The results demonstrated that retatrutide is not only a weight-loss agent but also a highly effective diabetes medication (Rosenstock et al., Lancet 2023).

Source: Rosenstock et al., Lancet 2023.

The HbA1c reductions of up to -2.2% at the 12 mg dose are among the largest ever reported for a single injectable agent, and 82% of participants at that dose achieved HbA1c ≤6.5% — essentially normoglycemic levels. The weight loss in this diabetes population (~16.9% at 12 mg) was lower than in the non-diabetic obesity trial, a pattern consistent with all incretin therapies (people with diabetes lose less weight on the same dose due to insulin resistance and metabolic differences).

Phase 2a: MASLD/NASH (Nature Medicine, 2024)

A substudy of the Phase 2 program examined retatrutide's effects on liver fat in participants with metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD) (Nature Medicine, 2024).

• Liver fat reduction at 12 mg: 82.4% (measured by MRI-PDFF)
• % achieving normal liver fat (<5%): 86% at the 12 mg dose
• Significant reductions in liver enzymes (ALT, AST) and inflammatory biomarkers

These results are extraordinary — an 82.4% reduction in liver fat is substantially greater than what has been reported for any other pharmacological agent, including tirzepatide's impressive SYNERGY-NASH data. The glucagon-driven hepatic lipid oxidation is the likely mechanism for this pronounced liver effect.

TRIUMPH Phase 3 Program

The Phase 3 program for retatrutide, branded as TRIUMPH, consists of four large registration trials:

TRIUMPH-4 Results (December 2025)

TRIUMPH-4 was the first Phase 3 trial to report results, enrolling participants with obesity and symptomatic knee osteoarthritis. The results exceeded even the already-impressive Phase 2 data (Eli Lilly press release):

• Weight loss at 12 mg (68 weeks): -28.7% of body weight (average 71.2 lbs / 32.3 kg lost)
• WOMAC pain scores: Reduced by 75.8% — a dramatic improvement in knee osteoarthritis symptoms
• Systolic blood pressure: Reduced by 14 mmHg

The 28.7% average weight loss at 68 weeks is the largest ever reported for a pharmaceutical agent in a controlled clinical trial. For context, the Roux-en-Y gastric bypass (the gold standard bariatric surgery) typically produces 25–35% weight loss at 1–2 years. Retatrutide is approaching surgical-level results without surgery.

The WOMAC pain score improvement is clinically significant — a 75.8% reduction means most participants experienced substantial or complete relief from their knee osteoarthritis symptoms, likely driven by the combination of massive weight loss reducing mechanical joint stress and potential anti-inflammatory effects of the drug.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing: The Titration Schedule

Phase 3 Titration Schedule (TRIUMPH Program)

Source: Clinical trial protocols for TRIUMPH-1 and TRIUMPH-4.

Phase 3 Maintenance Doses

The TRIUMPH trials are evaluating three potential maintenance doses: 4 mg, 9 mg, and 12 mg. This three-tier approach mirrors tirzepatide's strategy of offering multiple maintenance doses to allow individualized treatment based on each patient's balance of efficacy and tolerability. Not every patient may need the maximum 12 mg dose to achieve clinically meaningful results — though the Phase 2 data showed a clear dose-response relationship, with higher doses producing greater weight loss.

Why Start at 2 mg?

The 2 mg starting dose is intentionally sub-therapeutic for weight loss. Its purpose is to allow the gastrointestinal system to adapt to GLP-1 receptor agonism before the dose escalation introduces stronger GLP-1, GIP, and glucagon receptor activation. This is the same titration principle used by semaglutide (which starts at 0.25 mg) and tirzepatide (which starts at 2.5 mg). The gradual escalation significantly reduces the incidence and severity of nausea, vomiting, and diarrhea compared to starting at a therapeutic dose.

Administration Details

• Route: Subcutaneous injection
• Frequency: Once weekly
• Injection sites (expected): Abdomen, front of thigh, or upper arm — consistent with other subcutaneous injectables in this class
• Delivery device: Not finalized for commercial use. Clinical trials use pre-filled syringes or injection pens.
• Timing: Can be administered at any time of day, with or without meals (based on trial protocols)

How Dosing Compares to Other Agents

Retatrutide's titration is somewhat faster than both semaglutide and tirzepatide — reaching the maximum dose by week 13 versus week 17 (semaglutide) or week 21 (tirzepatide). This shorter ramp-up period may be clinically meaningful, as it means patients reach the most effective dose sooner, though it also means the GI adaptation window is compressed.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Data Shows

Weight Loss Comparison: How Retatrutide Stacks Up

Sources: STEP 1 (NEJM), SURMOUNT-1 (NEJM), Retatrutide Phase 2 (NEJM), TRIUMPH-4 (Eli Lilly).

Weight Loss Thresholds at 48 Weeks (Phase 2, 12 mg)

Weight-loss thresholds help clinicians and patients understand the probability of achieving clinically meaningful results. Here is how participants at the 12 mg dose performed at 48 weeks:

Source: Jastreboff et al., NEJM 2023.

These numbers are remarkable. Every single participant at the two highest doses lost at least 5% of body weight, and the vast majority lost far more. For comparison, in semaglutide's STEP 1 trial, approximately 86% of participants achieved ≥5% weight loss at 68 weeks.

TRIUMPH-4 Detailed Results (68 Weeks)

The TRIUMPH-4 trial provides the most recent and most impressive data point for retatrutide:

• Average weight loss at 12 mg: 28.7% (71.2 lbs / 32.3 kg)
• WOMAC knee pain improvement: 75.8% reduction in pain scores
• Systolic blood pressure reduction: 14 mmHg
• Population: Adults with obesity and symptomatic knee osteoarthritis

The 14 mmHg systolic blood pressure reduction is clinically significant on its own — for reference, a typical antihypertensive medication reduces SBP by 8–12 mmHg. The combined weight loss and blood pressure improvement suggest substantial cardiovascular risk reduction, though dedicated cardiovascular outcomes data will come from TRIUMPH-3.

Timeline: What to Expect

Based on Phase 2 and TRIUMPH-4 data, the following timeline represents approximate weight-loss expectations at the 12 mg dose (note: this is investigational and not yet available outside clinical trials):

Glycemic Results (Type 2 Diabetes)

In the Phase 2 diabetes trial, retatrutide demonstrated glycemic control rivaling the best available therapies:

• HbA1c reduction at 12 mg: -2.2% (from a baseline of ~8.3%)
• Percentage reaching HbA1c ≤6.5%: 82% at 12 mg
• Percentage reaching HbA1c <5.7% (normal): Substantial proportion, exact figure pending full Phase 3 data
• Fasting glucose reduction: Significant across all doses

For context, the best HbA1c reductions reported with tirzepatide in the SURPASS trials were -2.37% to -2.58%, and semaglutide in the SUSTAIN trials achieved up to -1.8%. Retatrutide's -2.2% at 12 mg in a 36-week trial is highly competitive, and longer Phase 3 trials may show even greater improvements.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Gastrointestinal Side Effects by Dose (Phase 2 Obesity Trial)

Source: Jastreboff et al., NEJM 2023. Note: Ranges reflect different titration schedules tested in the Phase 2 trial; some arms used faster escalation, which produced higher GI rates.

The wide ranges in the 4 mg and 8 mg columns reflect an important finding from the Phase 2 trial: the speed of titration significantly affected GI side-effect rates. Arms that escalated more quickly to higher doses had substantially more nausea and vomiting than arms that used gradual escalation. This directly informed the titration schedule chosen for Phase 3 (the 2 mg → 4 mg → 8 mg → 12 mg schedule over 12 weeks), which was designed to optimize the balance between reaching an effective dose quickly and minimizing GI intolerance.

Heart Rate Increase

One of the most closely watched safety signals for retatrutide is its effect on heart rate. In Phase 2 trials, retatrutide was associated with increases in resting heart rate of approximately 5–10 beats per minute (bpm) at higher doses. This is notably higher than semaglutide (which typically increases heart rate by ~3–4 bpm) and tirzepatide (2–4 bpm).

The clinical significance of this heart rate increase is still being evaluated. For context:

• A 5–10 bpm increase in a resting heart rate of 70 bpm represents a 7–14% increase
• This is within the range typically seen with moderate physical activity or caffeine intake
• The glucagon component likely contributes to this effect, as glucagon has known chronotropic (heart-rate-increasing) properties
• Whether this translates to any cardiovascular risk will be clarified by the Phase 3 program, particularly TRIUMPH-3 (the cardiovascular outcomes trial)

Discontinuation Rates

In the Phase 2 obesity trial, discontinuation due to adverse events ranged from 6% to 16% depending on dose and titration schedule. For comparison, semaglutide (Wegovy) has a discontinuation rate of approximately 7%, and tirzepatide (Zepbound) ranges from 4.3% to 6.6% in the SURMOUNT trials. The higher discontinuation rate at the top of retatrutide's range is largely attributable to the faster titration arms in Phase 2; the Phase 3 schedule (gradual 4-week increments) is expected to produce rates closer to the 6% lower bound.

Serious Adverse Events

In Phase 2, the rate of serious adverse events (SAEs) was approximately 4%, which was comparable to the placebo group. No specific pattern of serious adverse events emerged that would raise safety concerns beyond those already known for the GLP-1 drug class:

• Pancreatitis: A known class risk for GLP-1 receptor agonists. Monitor for persistent, severe abdominal pain.
• Gallbladder disease: Rapid weight loss increases gallstone risk. This is expected to be relevant for retatrutide given the magnitude of weight loss.
• Hypoglycemia: Low risk when used alone (glucose-dependent insulin secretion from GIP and GLP-1). The glucagon component may actually provide a safety buffer against hypoglycemia, though this remains to be confirmed in larger trials.
• Thyroid tumors: Animal-study findings relevant to the GLP-1 drug class. The same precautionary warnings that apply to semaglutide and tirzepatide will likely apply to retatrutide.

Practical Management

While retatrutide is not yet available for prescription, the principles for managing GI side effects are the same as for other GLP-1-based therapies:

• Smaller, more frequent meals to avoid triggering nausea from delayed gastric emptying
• Avoid high-fat, fried, and heavy foods during dose escalation
• Stay well hydrated — dehydration from vomiting or diarrhea can lead to serious complications
• Follow the titration schedule without skipping ahead to higher doses
• Report sustained or worsening symptoms to the clinical trial team or prescribing physician

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Ongoing Research

MASLD / NASH (Liver Disease)

The Phase 2a MASLD data for retatrutide is arguably the most impressive liver fat reduction ever reported for a pharmaceutical agent. At the 12 mg dose, retatrutide produced an 82.4% reduction in liver fat as measured by MRI-PDFF, and 86% of participants achieved normal liver fat levels (<5%) (Nature Medicine, 2024).

For context, tirzepatide's SYNERGY-NASH trial — itself considered a breakthrough — showed MASH resolution in up to 74% of participants. Retatrutide appears to go further, likely because the glucagon receptor activation directly stimulates hepatic lipid oxidation (the liver burning its own stored fat). This dual mechanism of weight loss (reducing fat delivery to the liver) plus direct hepatic lipid burning (glucagon effect) produces results that neither GLP-1-only nor dual-agonist drugs can match.

Dedicated Phase 3 trials for MASLD/NASH are expected, though the timeline depends on the primary obesity/diabetes program results. If confirmed, retatrutide could become a first-line treatment for a disease that affects an estimated 25% of the global population and currently has very limited pharmacological options.

Osteoarthritis

TRIUMPH-4's results in knee osteoarthritis were striking — a 75.8% reduction in WOMAC pain scores. Obesity is the single strongest modifiable risk factor for knee osteoarthritis, and the massive weight loss achieved with retatrutide directly reduces the mechanical load on weight-bearing joints. There may also be anti-inflammatory effects contributing to pain relief, as both GLP-1 and glucagon receptor activation have been associated with reduced systemic inflammation.

This opens the possibility of retatrutide receiving a specific indication for obesity with osteoarthritis, similar to how tirzepatide (Zepbound) received a specific indication for obesity with OSA.

Obstructive Sleep Apnea (OSA)

Given tirzepatide's success in SURMOUNT-OSA (which led to an FDA-approved OSA indication), retatrutide's even greater weight loss could produce even larger improvements in apnea-hypopnea index (AHI) and other OSA measures. No dedicated OSA trial for retatrutide has been announced yet, but the TRIUMPH-3 cardiovascular outcomes trial may capture OSA-related endpoints as secondary measures.

Cardiovascular Outcomes

TRIUMPH-3 (NCT05882045) is specifically enrolling patients with obesity and established cardiovascular disease. This trial will determine whether retatrutide's weight loss, blood pressure reduction, lipid improvements, and metabolic effects translate into reduced cardiovascular events (heart attack, stroke, cardiovascular death). Given the 14 mmHg systolic blood pressure reduction seen in TRIUMPH-4, expectations are high.

The glucagon component adds an interesting dimension to the cardiovascular story. Glucagon-driven energy expenditure and lipid oxidation could provide cardiovascular benefits independent of weight loss — but the heart rate increase (5–10 bpm) is a signal that requires careful evaluation in a cardiovascular population.

Cancer

A 2025 publication in npj explored the potential relationship between GLP-1-based therapies and cancer risk. While the data is preliminary and observational, the metabolic improvements associated with incretin therapies (reduced insulin resistance, reduced inflammation, weight loss) are all factors that reduce cancer risk. Whether retatrutide's more potent metabolic effects translate into greater cancer risk reduction remains to be studied, but the hypothesis is biologically plausible and an active area of investigation.

Comparison With Bariatric Surgery

With weight loss approaching 29% at 68 weeks, retatrutide enters the range historically associated only with bariatric surgery. This raises the question of whether pharmacological treatment could eventually serve as an alternative to surgery for some patients. Key considerations:

• Efficacy overlap: Roux-en-Y gastric bypass produces ~25–35% weight loss at 1–2 years; retatrutide's 28.7% at 68 weeks falls within this range
• Reversibility: Unlike surgery, stopping retatrutide would allow weight regain (as seen with all chronic disease medications when discontinued)
• Safety profile: Surgical complications (bleeding, infection, nutritional deficiencies) vs. pharmacological side effects (GI symptoms, heart rate increase)
• Cost: Unknown for retatrutide; bariatric surgery costs $15,000–35,000 but is a one-time expense vs. ongoing medication
• Long-term data: Surgery has decades of follow-up; retatrutide has <2 years of Phase 3 data

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost & Access

Current Availability

As of March 2026, retatrutide is not approved by the FDA and is not commercially available anywhere in the world. It cannot be purchased at pharmacies, through telehealth platforms, or from compounding pharmacies. The only way to receive retatrutide is by enrolling in an active clinical trial.

How to Access Retatrutide Now

The only legitimate way to receive retatrutide is through Eli Lilly's TRIUMPH Phase 3 clinical trial program. Trial sites are located across the United States and internationally.

• Check eligibility: Visit ClinicalTrials.gov — TRIUMPH-1 for obesity/overweight trials
• Type 2 diabetes: Visit ClinicalTrials.gov — TRIUMPH-2
• Eli Lilly trial finder: Visit LillyTrialGuide.com

Clinical trial participation is free — participants receive the medication at no cost and are compensated for visits.

Expected Pricing (Once Approved)

Eli Lilly has not announced pricing for retatrutide. However, pricing for comparable injectable weight-loss medications provides context:

Prices reflect U.S. wholesale acquisition cost (WAC) without insurance or manufacturer discounts.

As a first-in-class triple agonist with potentially superior efficacy, retatrutide may be priced at or above current GLP-1 medications. However, Eli Lilly's competitive pricing strategy with Zepbound (priced below Wegovy) suggests they may position retatrutide competitively.

Insurance Coverage Outlook

Insurance coverage will depend on the FDA-approved indication:

• Type 2 diabetes indication: Likely to receive broader insurance coverage, similar to Mounjaro
• Obesity/weight management indication: Coverage varies significantly — many insurers and Medicare currently exclude anti-obesity medications, though this landscape is evolving
• Medicare: The Treat and Reduce Obesity Act, if passed, could mandate Medicare coverage for anti-obesity drugs

Compounding Status

Retatrutide is not available from compounding pharmacies. Unlike semaglutide (which appeared on the FDA drug shortage list, temporarily allowing compounding), retatrutide has no FDA approval and no shortage designation. Compounding an unapproved drug is illegal under federal law.

International Availability

Retatrutide is not approved in any country. Eli Lilly is expected to pursue regulatory approval in the U.S., EU, and other major markets following completion of the TRIUMPH Phase 3 program. International availability will lag behind U.S. approval by 6–18 months based on typical regulatory timelines.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Pipeline: Where Retatrutide Stands

Regulatory Timeline

Competitive Landscape

Retatrutide enters an increasingly crowded field of next-generation metabolic therapies. Here is how the major pipeline agents compare:

Note: Weight loss figures are not directly comparable across trials due to differences in populations, durations, and study designs.

Eli Lilly's Portfolio Strategy

Eli Lilly is uniquely positioned with two separate next-generation agents:

• Orforglipron: An oral GLP-1 receptor agonist that would provide a daily-pill option for patients who prefer not to inject. Phase 3 trials are ongoing. While less potent than injectable options, the convenience of oral dosing is a major differentiator.
• Retatrutide: The injectable triple agonist that produces maximum weight loss. Positioned as the highest-efficacy option for patients who need the most aggressive pharmacological approach.

Together with tirzepatide (already approved), Eli Lilly would have a portfolio spanning the full spectrum of patient needs: moderate weight loss with an oral agent (orforglipron), strong weight loss with a proven dual agonist (tirzepatide), and maximum weight loss approaching surgical levels with a triple agonist (retatrutide).

Key Questions for Retatrutide's Approval

• Will TRIUMPH-1 confirm Phase 2 results? Phase 2 trials are smaller and can overestimate or underestimate treatment effects. The larger TRIUMPH-1 trial (~4,000 participants expected) will provide the definitive efficacy dataset.
• How will the heart rate signal look in larger populations? The 5–10 bpm increase seen in Phase 2 needs to be characterized in Phase 3, particularly in the TRIUMPH-3 cardiovascular population.
• What discontinuation rate will emerge? The 6–16% Phase 2 range is wide. Phase 3 with its optimized titration schedule should narrow this.
• Will the FDA require a cardiovascular outcomes trial before approval? Likely not for the primary obesity indication, but TRIUMPH-3 data may need to demonstrate at least neutral cardiovascular safety.
• Pricing: With tirzepatide already priced at ~$1,060/month, where Eli Lilly positions retatrutide will significantly affect market uptake.

What This Means for Patients

Retatrutide is not available for purchase, prescription, or compounding. It can only be accessed through enrollment in the TRIUMPH clinical trials. Patients interested in participating can search for active trial sites at ClinicalTrials.gov (TRIUMPH-1) or ClinicalTrials.gov (TRIUMPH-2).

If Phase 3 data is positive and regulatory review proceeds on schedule, the earliest retatrutide could be commercially available is mid-to-late 2027. In the meantime, patients seeking pharmacological weight management should discuss currently available options with their healthcare provider, including semaglutide (Wegovy) and tirzepatide (Zepbound).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Is retatrutide available now?

Answer: No. Retatrutide is an investigational drug currently in Phase 3 clinical trials. It has not been approved by the FDA or any other regulatory agency. The only way to access retatrutide today is through enrollment in a TRIUMPH clinical trial. Any website or provider claiming to sell or prescribe retatrutide outside of a clinical trial is operating illegally. The earliest retatrutide could be commercially available is mid-to-late 2027, assuming Phase 3 results are positive and the FDA review proceeds on a standard timeline.

How is retatrutide different from Ozempic (semaglutide) and Mounjaro (tirzepatide)?

Answer: All three drugs belong to the incretin therapy family but target different numbers of receptors. Semaglutide (Ozempic/Wegovy) targets one receptor (GLP-1). Tirzepatide (Mounjaro/Zepbound) targets two (GIP + GLP-1). Retatrutide targets three (GIP + GLP-1 + glucagon). The critical addition of the glucagon receptor means retatrutide not only suppresses appetite (like the other two) but also increases energy expenditure through thermogenesis. This dual mechanism — eating less and burning more — appears to explain why retatrutide produces ~28.7% weight loss versus ~22.5% for tirzepatide and ~14.9% for semaglutide. They are made by different manufacturers: semaglutide by Novo Nordisk, tirzepatide and retatrutide both by Eli Lilly.

Will insurance cover retatrutide?

Answer: This is unknown until the drug receives FDA approval and a commercial price is set. If approved, coverage will depend on the same factors that currently affect tirzepatide and semaglutide: the specific indication (obesity vs. diabetes), the patient's insurance plan, prior authorization requirements, and whether the plan excludes anti-obesity medications. Given the magnitude of the efficacy data and the growing evidence that pharmacological obesity treatment reduces downstream healthcare costs, there is reason to be cautiously optimistic about coverage — but this is speculative until Eli Lilly announces pricing and payers set their formulary decisions.

Can I get retatrutide compounded?

Answer: No. Compounding pharmacies can only compound drugs that contain FDA-approved active ingredients or bulk drug substances that appear on the FDA's approved list. Retatrutide has no FDA approval and is not on any compounding list. Any entity claiming to compound or sell retatrutide is operating outside the law, and there is no way to verify the identity, purity, or safety of such a product. Do not purchase retatrutide from any online source.

What about the heart rate increase? Is it dangerous?

Answer: In Phase 2 trials, retatrutide increased resting heart rate by approximately 5–10 bpm — higher than the 3–4 bpm seen with semaglutide and the 2–4 bpm seen with tirzepatide. The clinical significance of this is not yet established. A 5–10 bpm increase is within the range of what happens with everyday activities like drinking coffee or mild stress. However, for patients with certain cardiovascular conditions (particularly arrhythmias or heart failure), even modest heart rate increases can be clinically relevant. The TRIUMPH-3 trial (which enrolls patients with cardiovascular disease) will provide critical data on whether this signal translates to any increased cardiovascular risk. Until that data is available, the heart rate increase is being closely monitored but has not raised safety concerns serious enough to slow the clinical program.

Will retatrutide cause muscle loss?

Answer: Any weight loss — from diet, surgery, or medication — results in loss of both fat mass and lean mass. The greater the weight loss, the greater the absolute lean mass lost. At ~28.7% body weight reduction, some lean mass loss is inevitable. Phase 2 data on body composition has not been fully published, but the pattern is expected to be similar to what is seen with tirzepatide and semaglutide: approximately 60–70% fat mass and 30–40% lean mass. Resistance training and adequate protein intake remain the most important strategies for preserving lean mass during pharmacological weight loss. Some next-generation agents (like Amgen's MariTide, which targets activin receptors) are specifically designed to preserve muscle — whether retatrutide needs to be combined with such approaches is an open question.

Why would I choose retatrutide over tirzepatide if both are from Eli Lilly?

Answer: This comparison will become clinically relevant once retatrutide is approved. Based on the data so far: retatrutide produces approximately 6 percentage points more weight loss than tirzepatide (~28.7% vs. ~22.5%). It also produces dramatically greater liver fat reduction. However, it has a higher heart rate increase and potentially more GI side effects. The choice would depend on individual patient needs: someone who needs maximal weight loss or has significant liver disease might benefit from retatrutide, while someone who achieves their goals with less aggressive treatment might do well on tirzepatide. Having both options available would allow physicians to personalize treatment.

How close is retatrutide to bariatric surgery results?

Answer: Very close. Roux-en-Y gastric bypass (RYGB) produces approximately 25–35% weight loss at 1–2 years. Retatrutide's 28.7% at 68 weeks falls squarely within that range. Sleeve gastrectomy produces somewhat less (~20–25%). However, important caveats apply: (1) surgery is a one-time intervention while medication must be continued indefinitely, (2) surgical results have 20+ years of follow-up while retatrutide has <2 years, and (3) surgical patients often have additional metabolic benefits from gut hormone changes beyond weight loss. Still, for the first time, a pharmaceutical agent is producing weight loss that overlaps with surgical outcomes — a milestone in obesity medicine.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

The evidence to date clearly shows:

• Most potent weight-loss agent ever tested: Up to 28.7% body weight reduction at 68 weeks (TRIUMPH-4), and 24.2% at just 48 weeks in Phase 2 — with the weight-loss curve still not plateauing (NEJM, 2023; Eli Lilly, 2025)
• Approaches bariatric surgery results: The 28.7% weight loss at 12 mg overlaps with Roux-en-Y gastric bypass outcomes (25–35%) — a first for any pharmaceutical agent
• Unique triple-agonist mechanism: The only drug in development that targets GIP, GLP-1, and glucagon receptors simultaneously, both reducing caloric intake and increasing energy expenditure
• Exceptional liver fat reduction: 82.4% reduction in liver fat with 86% of patients achieving normal levels — potentially transformative for MASLD/NASH treatment (Nature Medicine, 2024)
• Strong glycemic control: HbA1c reductions of up to -2.2% with 82% of diabetes patients reaching ≤6.5% (Lancet, 2023)
• Significant blood pressure and pain benefits: 14 mmHg SBP reduction and 75.8% improvement in knee osteoarthritis pain (TRIUMPH-4)
• GI side effects are manageable: Consistent with the GLP-1 class; gradual titration mitigates nausea and vomiting
• Heart rate increase requires monitoring: 5–10 bpm increase is higher than semaglutide or tirzepatide; Phase 3 cardiovascular data will clarify significance
• Not yet available: Phase 3 ongoing, potential FDA approval mid-to-late 2027

Retatrutide represents a potential paradigm shift in obesity treatment. For the first time, a pharmaceutical agent is producing weight loss that rivals bariatric surgery, while simultaneously addressing liver disease, diabetes, and cardiovascular risk factors. The triple-agonist mechanism — particularly the addition of glucagon-driven energy expenditure — is a fundamentally different approach that explains why retatrutide outperforms both single- and dual-agonist drugs.

The key uncertainty is whether the Phase 3 TRIUMPH program will confirm these results in larger, longer, and more diverse populations. If it does, retatrutide would represent the most significant advance in pharmacological obesity treatment since the advent of GLP-1 receptor agonists. The cardiovascular safety data (particularly the heart rate signal) will be the most scrutinized aspect of the Phase 3 program.

For patients and clinicians watching this space: retatrutide is not a reason to delay treatment with currently available options. Semaglutide and tirzepatide are FDA-approved, proven effective, and available today. But retatrutide — if it delivers on its Phase 2 promise — could redefine what is pharmacologically possible for obesity and its associated conditions.

Questions to Watch For

• Will TRIUMPH-1 confirm ~25–29% weight loss in a larger obesity population?
• What is the cardiovascular safety profile in TRIUMPH-3?
• How will Eli Lilly price retatrutide relative to tirzepatide?
• Will the FDA grant priority review?
• How will insurance coverage develop for a drug with this level of efficacy?
• Will the liver fat data lead to a dedicated MASLD/NASH indication?
• How does long-term weight maintenance compare with tirzepatide and surgery?

Sources & Further Reading

Phase 2 Clinical Trials

• Jastreboff et al. (2023) — "Triple-Hormone-Receptor Agonist Retatrutide for Obesity" (NEJM)
• Rosenstock et al. (2023) — "Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes" (Lancet) — PMID: 37366315
• Phase 2 Obesity Trial — NCT04881760 (ClinicalTrials.gov)

Phase 2a MASLD/NASH

• Retatrutide Phase 2a MASLD Substudy (Nature Medicine, 2024) — PMID: 38858523

TRIUMPH Phase 3 Program

• TRIUMPH-1: Obesity / Overweight — NCT05929066 (ClinicalTrials.gov)
• TRIUMPH-2: Type 2 Diabetes + Obesity — NCT05929079 (ClinicalTrials.gov)
• TRIUMPH-3: Obesity + Cardiovascular Disease — NCT05882045 (ClinicalTrials.gov)
• TRIUMPH-4: Obesity + Knee Osteoarthritis — NCT05931367 (ClinicalTrials.gov)

TRIUMPH-4 Results

• Eli Lilly Press Release — TRIUMPH-4 Retatrutide Results (December 2025)

Manufacturer Information

• Eli Lilly — What to Know About Retatrutide

Related GLPbase Articles

• Semaglutide: The Complete Guide
• Tirzepatide: The Complete Guide
• GLP-1 Medication Comparison
• Next-Generation Pipeline Overview

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.